A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer

Carcinogenesis
Batoul FarranCathryn H Bock

Abstract

Prostate cancer is one of the most common cancers in men worldwide. Currently available diagnostic and prognostic tools for this disease, such as prostate specific antigen, suffer from lack of specificity and sensitivity, resulting in over- and misdiagnosis. Hence, there is an urgent need for clinically relevant biomarkers capable of distinguishing between aggressive and nonaggressive forms of prostate cancer to aid in stratification, management and therapeutic decisions. To address this unmet need, we investigated the patterns of expression of a panel of 68 plasma-derived microRNAs (miRNAs) in a cohort of African American (AA) and European American (EA) prostate cancer patients (n = 114). miRNA qPCR results were analyzed using in-depth statistical methods, and a bioinformatics analysis was conducted to identify potential targets of the differentially expressed miRNAs. Our data demonstrate that a new previously unreported circulating miRNA signature consisting of a combination of interacting miRNAs (miR-17/miR-192) and an independent miRNA (miR-181a) are capable of segregating aggressive and nonaggressive prostate cancer in both AA and EA patients. The interacting miRNAs outperformed independent miRNAs in identifying aggressive...Continue Reading

References

Feb 15, 1977·Biochemical Pharmacology·R L Vigdahl, R H Tukey
Feb 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stefano VoliniaCarlo M Croce
Oct 25, 2006·Nature Reviews. Cancer·George A Calin, Carlo M Croce
Jun 15, 2007·Journal of Cellular Physiology·Asish K Ghosh, John Varga
Jul 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Patrick S MitchellMuneesh Tewari
Jan 6, 2010·Genes & Development·Gijs van Haaften, Reuven Agami
Jan 14, 2012·British Journal of Cancer·R J BryantF C Hamdy
Apr 5, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·D Maxwell ParkinAhmedin Jemal
May 16, 2015·Nucleic Acids Research·Ioannis S VlachosArtemis G Hatzigeorgiou
Oct 22, 2015·International Journal of Cancer. Journal International Du Cancer·Cindy Ke ZhouSusan S Devesa
Oct 28, 2015·Prostate Cancer and Prostatic Diseases·V MouravievR J Perera
Jan 9, 2016·International Journal of Molecular Medicine·Jiantao SunQingxiang Huo
Jan 26, 2016·European Urology·Linda FabrisGeorge A Calin
Feb 6, 2016·The Prostate·Seodhna M LynchDeclan J McKenna
Apr 5, 2016·Nature Communications·Sherry Y WuAnil K Sood
Nov 5, 2016·Frontiers in Bioscience (Landmark Edition)·Clayton YatesLara Sucheston-Campbell
Nov 29, 2016·Urologic Oncology·Kamla Kant ShuklaParveen Sharma
Dec 3, 2016·Nucleic Acids Research·Minoru KanehisaKanae Morishima
Jan 7, 2017·Clinical Science·Helen M WiseNicholas R Leslie

❮ Previous
Next ❯

Citations

Apr 9, 2020·Epigenomics·Irena AbramovicNino Sincic
Aug 8, 2018·International Journal of Oncology·Alessia FinottiRoberto Gambari
Apr 4, 2021·Pharmaceutics·Noemi Arrighetti, Giovanni Luca Beretta
Jun 29, 2021·Systems Biology in Reproductive Medicine·Gisela LorenteDavid Miller
Dec 9, 2020·Analytical Chemistry·Abby L JonesJames F Rusling
Dec 22, 2021·Bioscience Reports·M Y Cynthia StaffordDeclan J McKenna

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Related Papers

Drug Delivery and Translational Research
Christa HaldrupKarina D Sorensen
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Kefeng XiaoLingwu Chen
Frontiers in Bioscience (Landmark Edition)
Clayton YatesLara Sucheston-Campbell
© 2022 Meta ULC. All rights reserved